background

Investment Committee

Rory Riggs

Co-founder and chairman of the Investment Committee

Mr. Riggs co-founded Royalty Pharma in 1996 and assumed the role of chairman in 2003. Mr. Riggs is the founder & CEO of Syntax & Locus Analytics. Previously, Mr. Riggs was President of Biomatrix. Mr. Riggs serves or has served on several boards including Fibrogen, Cibus, Sugen, Intra-cellular Therapies and Biomatrix. Mr. Riggs has a BA from Middlebury College and an MBA from Columbia University.

Pablo Legorreta

Founder and Chief Executive Officer

Mr. Legorreta has over 20 years of experience investing in pharmaceutical royalties, and building and managing a rapidly growing life sciences investment company that is today one of the largest dedicated life sciences investors in the world. Prior to founding Royalty Pharma in 1996, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of the Hospital for Special Surgery, Rockefeller University, Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur), Open Medical Institute, and Park Avenue Armory. Mr. Legorreta is the founder and chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities. Mr. Legorreta has a degree in industrial engineering from Universidad Iberoamericana in Mexico City.

Germano Giuliani

Mr. Giuliani is the former chief financial officer, chairman and chief executive officer of Giuliani SpA. Mr. Giuliani serves or has served on several boards including Giuliani SpA, Giuliani Group SpA, Recordati SpA (incl. Compensation Committee), Nographarma Ltd, Nogra Group SA, HBM Healthcare Investment AG (incl. Compensation Committee), Fair Med Healthcare AG, Jukka LLC USA, NGR (MONACO) SAM, Nogra Pharma Invest Sarl, Nogra Private Equity Sarl, Nogra Real Estate Sarl, Steering Committee for GiSev Family Office SA, and Mosaix Ventures LLP USA. Mr. Giuliani has a degree in economics and commerce from the Catholic University of the Sacred Heart in Milan, Italy and a MA in corporate finance from Università Commerciale Luigi Bocconi in Milan, Italy.

Stanislas Poniatowski

Mr. Poniatowski is the chairman of the board of Quilvest and Partners (Luxembourg). Mr. Poniatowski is also a board member of International Advisory Services, Terold S.A., Grupo Peñaflor, Tiendas BBB, chairman of HBM Partners, and StarTeq Holding. Previously, Mr. Poniatowski was a senior banker and managing director at Lazard Frères. Mr. Poniatowski has a degree in financial management from Ecole des Cadres in Paris-Neuilly, France. Mr. Poniatowski is also the chairman of Foundation ARPE, a non-profit in Switzerland.

Carlos Rodriguez-Pastor

Mr. Rodriguez Pastor is the chairman and chief executive officer of Grupo Interbank (Peru). Previously, Mr. Rodriguez-Pastor held various management positions at Chemical Bank, PaineWebber, Citibank and Banco Santander. Mr. Rodriguez-Pastor has a BA in social sciences from UC-Berkeley and an MBA from the Amos Tuck School at Dartmouth College.

Errol De Souza, PhD

Dr. De Souza is the president and chief executive officer of Neuropore Therapies. Previously, Dr. De Souza held various management positions at companies including Biodel, Neurocrine Biosciences, Synaptic Pharmaceutical Corp, and Sanofi. Dr. De Souza serves or has served on several editorial boards and National Institutes of Health committees as well as on the board of directors of several private and public companies. Dr. De Souza has a BA in physiology from the University of Toronto and a PhD in neuroendocrinology from the University of Toronto and was a postdoctoral fellow in neuroscience at The Johns Hopkins University School of Medicine.

Greg Norden

Mr. Norden is the managing director of G9 Capital Group, LLC. Previously, Mr. Norden was senior vice president and chief financial officer at Wyeth. Mr. Norden also serves or has served on several boards including Zoetis, Univision, NanoString Technologies, Entasis Therapeutics, Welch Allyn and Human Genome Sciences. Mr. Norden has a BS in management and economics from the State University of New York at Plattsburgh and an MS in accounting from Long Island University – C.W. Post.